Overview

Apolipoprotein CIII Reduction Via Colchicine

Status:
Completed

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

Summary

The aim of this trial will be to determine an effect-size for the administration of chronic low-dose colchicine in the reduction of serum levels of triglycerides (TG), very-low density lipoproteins (VLDL), and apolipoprotein CIII (apoCIII) in human subjects over a period of 4-6 weeks.

Phase:

Early Phase 1

Details

Lead Sponsor:

Scripps Translational Science Institute

Treatments:

Colchicine